Literature DB >> 25657060

Admission blood pressure and 1-year mortality in acute myocardial infarction.

D Roth1, R Van Tulder1, B Heidinger1, H Herkner1, W Schreiber1, C Havel1.   

Abstract

AIMS: Arterial hypertension is a well-established factor for increased risk of cardiovascular diseases, but low admission blood pressure has also been suggested as predictor for increased mortality. We hypothesised that in patients with acute myocardial infarction admission blood pressure at the Emergency Department predicts long-term mortality.
METHODS: We included consecutive patients treated for acute myocardial infarction (AMI) at our 2,200-bed tertiary care hospital from 1991 to 2009 into our cohort. Systolic, diastolic and pulse pressure on admission were analysed as main predictors for 1-year mortality. We adjusted for several baseline factors and tested for interactions using multivariable regression models.
RESULTS: We included 3943 patients among whom 3604 were alive after 1 year. With increasing admission blood pressure 1-year mortality risk decreased incrementally to a 70% reduced relative risk in the highest blood pressure categories vs. the lowest categories. This effect was independent of blood pressure modifying interventions.
CONCLUSIONS: In acute myocardial infarction, admission blood pressure predicts long-term mortality in an inverse relation. With increasing admission blood pressure long-term mortality decreases. Low admission blood pressure should serve as a warning sign in patients with AMI. Admission blood pressure should therefore be interpreted in opposite to the regular, preventive, point of view.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25657060     DOI: 10.1111/ijcp.12588

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  6 in total

1.  Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis.

Authors:  Giuliano Tocci; Emanuele Barbato; Roberta Coluccia; Anna Modestino; Beniamino Pagliaro; Vittoria Mastromarino; Francesca Giovannelli; Andrea Berni; Massimo Volpe
Journal:  Am J Hypertens       Date:  2015-08-13       Impact factor: 2.689

2.  Early blood pressure assessment after acute myocardial infarction: Insights using digital health technology.

Authors:  Rongzi Shan; Jie Ding; Daniel Weng; Erin M Spaulding; Shannon Wongvibulsin; Matthias A Lee; Ryan Demo; Francoise A Marvel; Seth S Martin
Journal:  Am J Prev Cardiol       Date:  2020-09-17

Review 3.  Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective.

Authors:  Konstantinos Konstantinou; Costas Tsioufis; Areti Koumelli; Manos Mantzouranis; Alexandros Kasiakogias; Michalis Doumas; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-12       Impact factor: 3.738

4.  Rapid predictors for the occurrence of reduced left ventricular ejection fraction between LAD and non-LAD related ST-elevation myocardial infarction.

Authors:  Zhang-Wei Chen; Zi-Qing Yu; Hong-Bo Yang; Ying-Hua Chen; Ju-Ying Qian; Xian-Hong Shu; Jun-Bo Ge
Journal:  BMC Cardiovasc Disord       Date:  2016-01-05       Impact factor: 2.298

5.  Targeting low-normal or high-normal mean arterial pressure after cardiac arrest and resuscitation: a randomised pilot trial.

Authors:  Pekka Jakkula; Ville Pettilä; Markus B Skrifvars; Johanna Hästbacka; Pekka Loisa; Marjaana Tiainen; Erika Wilkman; Jussi Toppila; Talvikki Koskue; Stepani Bendel; Thomas Birkelund; Raili Laru-Sompa; Miia Valkonen; Matti Reinikainen
Journal:  Intensive Care Med       Date:  2018-11-15       Impact factor: 17.440

6.  The baseline and repeated measurements of DBP to assess in-hospital mortality risk among critically ill patients with acute myocardial infarction: A retrospective cohort study.

Authors:  Sulan Huang; Yanlan Luo; Li Liang; Ning Guo; Xiangjie Duan; Quan Zhou; Liangqing Ge
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.